•  
  •  
  •  
  •  

2025-12-20 00:50:34

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • South Indian Bank Introduces RuPay SIB Paytag
  • Nifty Bank reclaims 59,000 but lacks follow-through strength
  • Nifty Ends Four-Day Losing Streak on Strong Global Cues
  • HDFC SKY Expands MTF Universe with Addition of HDFC Gold ETF
  • Nifty breaks losing streak, but continues to trade in broader consolidation range

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Sai Life Sciences Releases Sustainability Report 2024-25
  • Pfizer & Cipla announce Exclusive Marketing and Distribution Partnership for Select Brands in India
  • Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India
  • Lupin signs exclusive licensing agreement with Neopharmed for Gastroenterology Brand Plasil® in the Philippines and Brazil
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • APL Healthcare Ltd's Unit-4 gets 5 observations from USFDA
  • US FDA determines Sun Pharma's Baska facility inspection classification as OAI
  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Datopotamab Deruxtecan powder
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab
  • Lupin receives EIR from US FDA for its Nagpur Injectable Facility
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Shelter Pharma Ltd secures order
  • Lupin Secures SBTi Validation for Emission Reduction Targets
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Akums introduces enhanced Gabapentin ER Formulation powered by RetenEx Technology for PHN Management
  • Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
  • Ind-Swift Laboratories Ltd receives GMP compliance certificate from NNGYK-Hungary
  • Shelter Pharma Limited Launches D3 Cure Capsules
  • Successful completion of USFDA inspection at Vizag facility
  • Caplin Point Laboratories Ltd's injectables facility completes INVIMA audit successfully
  • Apitoria Pharma Pvt Ltd receives 3 observations from USFDA for Unit-V
  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
  • Shilpa Medicare Receives Initial Authorization for Rotigotine Transdermal Patch from Europe

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • South Indian Bank Introduces RuPay SIB Paytag
  • Nifty Bank reclaims 59,000 but lacks follow-through strength
  • Nifty Ends Four-Day Losing Streak on Strong Global Cues
  • HDFC SKY Expands MTF Universe with Addition of HDFC Gold ETF
  • Nifty breaks losing streak, but continues to trade in broader consolidation range


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024